Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health

ConferencepositiveFoundayoretatrutideeloraTZPPositive

AI Analysis

Summary

Eli Lilly announced it will present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, with pivotal TRIUMPH-2 results showing retatrutide delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes patients.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

TRIUMPH-2 showed retatrutide delivered substantial weight loss and A1C improvements; ACHIEVE-4 reaffirmed Foundayo efficacy in type 2 diabetes

Importance:7/10

Sentiment:

0.75

EASD 2026 Conferenceweight lossdiabetesobesitycardiometabolic healthpivotal results

Related Companies

$LLY

Read the original article

Published by PR Newswire Biotech on September 15, 2026 10:45 AM

Read Original